within Pharmacolibrary.Drugs.ATC.H;

model H03BB52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 1.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Thiamazole, also known as methimazole, is an antithyroid drug primarily used to treat hyperthyroidism, including Graves' disease. It works by inhibiting the synthesis of thyroid hormones. Thiamazole is frequently used as first-line therapy for hyperthyroidism and is approved for clinical use. The ATC code H03BB52 refers to combinations of thiamazole with other drugs.</p><h4>Pharmacokinetics</h4><p>No direct population-specific pharmacokinetic (PK) data found for thiamazole in the specific combination form under ATC H03BB52. The following parameters are estimates based on available data for oral thiamazole administered alone in adult patients with hyperthyroidism.</p><h4>References</h4><ol><li><p>Izbicka, M, et al., &amp; Dec, R (2010). [Pharmacokinetics of digoxin in hyperthyroidism. Effect of methimazole]. <i>Wiadomosci lekarskie (Warsaw, Poland : 1960)</i> 63(1) 10–16. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20701025/&quot;>https://pubmed.ncbi.nlm.nih.gov/20701025</a></p></li><li><p>Salimi, A, et al., &amp; Mohammad Soleymani, S (2024). Development and optimization of a methimazole microemulsion for topical application: Formulation characteristics and transdermal permeation. <i>Journal of cosmetic dermatology</i> 23(12) 4315–4324. DOI:<a href=&quot;https://doi.org/10.1111/jocd.16528&quot;>10.1111/jocd.16528</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39135289/&quot;>https://pubmed.ncbi.nlm.nih.gov/39135289</a></p></li><li><p>Silva, MN, et al., &amp; Medeiros-Neto, G (2004). Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. <i>Clinical endocrinology</i> 60(3) 300–308. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2265.2003.01918.x&quot;>10.1046/j.1365-2265.2003.01918.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15008994/&quot;>https://pubmed.ncbi.nlm.nih.gov/15008994</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H03BB52;
